The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers.
 
Romel Somwar
No Relationships to Disclose
 
Roger Smith
No Relationships to Disclose
 
Takuo Hayashi
No Relationships to Disclose
 
Kota Ishizawa
No Relationships to Disclose
 
Alexandra Snyder Charen
Honoraria - Bristol-Myers Squibb; Merck; Syndax
Consulting or Advisory Role - Third Rock Ventures
 
Inna Khodos
No Relationships to Disclose
 
Marissa Mattar
No Relationships to Disclose
 
Jie He
Employment - Foundation Medicine
 
Sohail Balasubramanian
Employment - Foundation Medicine
 
Phil Stephens
Employment - Foundation Medicine
 
Doron Lipson
Employment - Foundation Medicine
 
Elisa de Stanchina
No Relationships to Disclose
 
Monika Davare
No Relationships to Disclose
 
Vincent A. Miller
Employment - Foundation Medicine
 
Gregory J. Riely
Honoraria - Celgene
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Novartis; Roche
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Genentech/Roche; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Emily Cheng
No Relationships to Disclose
 
Marc Ladanyi
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - NCCN/Boehringer Ingelheim
 
Alexander E. Drilon
Honoraria - Exelixis; Genentech/Roche; Ignyta
Consulting or Advisory Role - AstraZeneca; Exelixis; Genentech/Roche
Speakers' Bureau - Ignyta
Research Funding - Foundation Medicine
Travel, Accommodations, Expenses - AstraZeneca; Exelixis; Genentech/Roche; Ignyta